|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0013216,
umls-concept:C0023981,
umls-concept:C0026986,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0205088,
umls-concept:C0239307,
umls-concept:C0280449,
umls-concept:C1274040,
umls-concept:C1515895,
umls-concept:C1522609,
umls-concept:C1554112,
umls-concept:C1831743
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-10-4
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Allogeneic stem cell transplantation is usually considered the only curative treatment option for patients with advanced or transformed myelodysplastic syndromes in complete remission, but post-remission chemotherapy and autologous stem cell transplantation are potential alternatives, especially in patients over 45 years old.
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-26,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-27,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-28,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-29,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-30,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-31,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-32,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-33,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-34,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-35,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-36,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-37,
http://linkedlifedata.com/resource/pubmed/grant/5U10 CA11488-38
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
pubmed-author:AmadoriSergioS,
pubmed-author:BelhabriAminA,
pubmed-author:BiersackHaraldH,
pubmed-author:DelforgeMichelM,
pubmed-author:FerrantAugustinA,
pubmed-author:GratwohlAloisA,
pubmed-author:HagemeijerAnneA,
pubmed-author:Hellström-LindbergEvaE,
pubmed-author:JansenJoop HJH,
pubmed-author:KobbeGuidoG,
pubmed-author:KovacsovicsTiborT,
pubmed-author:MarieJean-PierreJP,
pubmed-author:MuusPetraP,
pubmed-author:OssenkoppeleGertG,
pubmed-author:SchoutenHarry CHC,
pubmed-author:SelleslagDominikD,
pubmed-author:SuciuStefanS,
pubmed-author:WijermansPierreP,
pubmed-author:WillemzeRoelR,
pubmed-author:de WitteTheoT
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1754-61
|
|
pubmed:meshHeading |
pubmed-meshheading:20494931-Adult,
pubmed-meshheading:20494931-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20494931-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:20494931-Humans,
pubmed-meshheading:20494931-Leukemia, Myeloid, Acute,
pubmed-meshheading:20494931-Middle Aged,
pubmed-meshheading:20494931-Myelodysplastic Syndromes,
pubmed-meshheading:20494931-Neoplasms, Second Primary,
pubmed-meshheading:20494931-Survival Analysis,
pubmed-meshheading:20494931-Transplantation, Autologous,
pubmed-meshheading:20494931-Transplantation, Homologous
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.
|
|
pubmed:affiliation |
Department of Tumorimmunology, Radboud University Medical Centre Nijmegen, Nijmegen, the Netherlands. t.deWitte@ncmls.ru.nl
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
